Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals
Identifieur interne : 001825 ( Main/Curation ); précédent : 001824; suivant : 001826Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals
Auteurs : Zhen Qi [États-Unis] ; Gary W. Miller [États-Unis] ; Eberhard O. Voit [États-Unis]Source :
- Synapse [ 0887-4476 ] ; 2009-12.
English descriptors
- KwdEn :
Abstract
Dopamine signaling is involved in a number of brain pathways, and its disruption has been suggested to be involved in the several disease states, including Parkinson's disease (PD), schizophrenia, and attention deficit hyperactivity disorder (ADHD). It has been hypothesized that altered storage, release, and reuptake of dopamine contributes to both the hypo‐ and hyperdopaminergic states that exist in various diseases. Here, we use our recently described mathematical model of dopamine metabolism, combined with a comprehensive Monte Carlo simulation analysis, to identify key determinants of dopamine metabolism associated with the dysregulation of dopamine homeostasis that may contribute to the pathogenesis of dopamine‐based disorders. Our model reveals that the dopamine transporter (DAT), the vesicular monoamine transporter (VMAT2), and the enzyme monoamine oxidase (MAO) are the most influential components controlling the synaptic level of dopamine and the formation of toxic intracellular metabolites. The results are consistent with experimental observations and point to metabolic processes and combinations of processes that may be biochemical drivers of dopamine neuron degeneration. Since many of the identified components can be targeted therapeutically, the model may aid in the design of combined therapeutic regimens aimed at restoring proper dopamine signaling with toxic intermediates under control. Synapse 63:1133–1142, 2009. © 2009 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/syn.20686
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A84
Links to Exploration step
ISTEX:4D8906CBF780D75F05A02C104E08EA32F5130E3DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals</title><author><name sortKey="Qi, Zhen" sort="Qi, Zhen" uniqKey="Qi Z" first="Zhen" last="Qi">Zhen Qi</name><affiliation wicri:level="2"><mods:affiliation>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Miller, Gary W" sort="Miller, Gary W" uniqKey="Miller G" first="Gary W." last="Miller">Gary W. Miller</name><affiliation wicri:level="2"><mods:affiliation>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Voit, Eberhard O" sort="Voit, Eberhard O" uniqKey="Voit E" first="Eberhard O." last="Voit">Eberhard O. Voit</name><affiliation wicri:level="2"><mods:affiliation>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D8906CBF780D75F05A02C104E08EA32F5130E3D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/syn.20686</idno><idno type="url">https://api.istex.fr/document/4D8906CBF780D75F05A02C104E08EA32F5130E3D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A84</idno><idno type="wicri:Area/Main/Curation">001825</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals</title><author><name sortKey="Qi, Zhen" sort="Qi, Zhen" uniqKey="Qi Z" first="Zhen" last="Qi">Zhen Qi</name><affiliation wicri:level="2"><mods:affiliation>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Miller, Gary W" sort="Miller, Gary W" uniqKey="Miller G" first="Gary W." last="Miller">Gary W. Miller</name><affiliation wicri:level="2"><mods:affiliation>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Voit, Eberhard O" sort="Voit, Eberhard O" uniqKey="Voit E" first="Eberhard O." last="Voit">Eberhard O. Voit</name><affiliation wicri:level="2"><mods:affiliation>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-12">2009-12</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1133">1133</biblScope><biblScope unit="page" to="1142">1142</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">4D8906CBF780D75F05A02C104E08EA32F5130E3D</idno><idno type="DOI">10.1002/syn.20686</idno><idno type="ArticleID">SYN20686</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biochemical Systems Theory</term><term>Monte Carlo method</term><term>Parkinson's disease</term><term>dopamine metabolism</term><term>dopamine nerve terminal</term><term>metabolic profile</term><term>personalized medicine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine signaling is involved in a number of brain pathways, and its disruption has been suggested to be involved in the several disease states, including Parkinson's disease (PD), schizophrenia, and attention deficit hyperactivity disorder (ADHD). It has been hypothesized that altered storage, release, and reuptake of dopamine contributes to both the hypo‐ and hyperdopaminergic states that exist in various diseases. Here, we use our recently described mathematical model of dopamine metabolism, combined with a comprehensive Monte Carlo simulation analysis, to identify key determinants of dopamine metabolism associated with the dysregulation of dopamine homeostasis that may contribute to the pathogenesis of dopamine‐based disorders. Our model reveals that the dopamine transporter (DAT), the vesicular monoamine transporter (VMAT2), and the enzyme monoamine oxidase (MAO) are the most influential components controlling the synaptic level of dopamine and the formation of toxic intracellular metabolites. The results are consistent with experimental observations and point to metabolic processes and combinations of processes that may be biochemical drivers of dopamine neuron degeneration. Since many of the identified components can be targeted therapeutically, the model may aid in the design of combined therapeutic regimens aimed at restoring proper dopamine signaling with toxic intermediates under control. Synapse 63:1133–1142, 2009. © 2009 Wiley‐Liss, Inc.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:4D8906CBF780D75F05A02C104E08EA32F5130E3D
|texte= Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals
}}
| This area was generated with Dilib version V0.6.23. |  |